Race, ethnicity, and use of thiazolidinediones among US adults with diabetes^*

References

• Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936–40
   PubMed Web of Science ®Google Scholar
• Engelgau MM, Geiss LS, Saaddine JB, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004;140: 945–50
   PubMed Web of Science ®Google Scholar
• Fan T, Koro CE, Fedder DO, Bowlin SJ. Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. from 1988 to 2002. Diabetes Care 2006;29:1924–5
   Google Scholar
• Lee JA, Liu CF, Sales AE. Racial and ethnic differences in diabetes care and health care use and costs. Prev Chronic Dis 2006;3:A85
   Google Scholar
• Bonds DE, Zaccaro DJ, Karter AJ, et al. Ethnic and racial differences in diabetes care: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2003;26:1040–6
   PubMed Web of Science ®Google Scholar
• Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002;136:565–74
   PubMed Web of Science ®Google Scholar
• Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403–8
   PubMed Web of Science ®Google Scholar
• Shaya FT, Shin JY, Mullins D, et al. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin. J Natl Med Assoc 2005;97:493–7
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. New Engl J Med 2004;351:1106–18
   PubMed Web of Science ®Google Scholar
• Kendall DM. Thiazolidinediones: the case for early use. Diabetes Care 2006;29:154–7
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–72
   PubMed Web of Science ®Google Scholar
• Koski RR. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. Diabetes Educ 2006;32:869–76
   PubMed Web of Science ®Google Scholar
• Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004;27:982–91
   Google Scholar
• Leiter LA. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabetic Med 2005;22:963–72
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Dagogo-Jack S. Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations. Ethn Dis 2006;16:51–7
   PubMed Web of Science ®Google Scholar
• Haffner SM, D’Agostino R, Saad MF, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites [The Insulin Resistance Atherosclerosis Study]. Diabetes 1996;45:742–8
   PubMed Web of Science ®Google Scholar
• Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 2003;52:2490–6
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality, Rockville (MD). Medical Expenditure Panel Survey. MEPS Survey Background. http://207.188.212.220/mepsweb/about_meps/survey_back.jsp [accessed December 5, 2006]
   Google Scholar
• Agency for Healthcare Research and Quality, Rockville (MD). MEPS-HC Sample Design and Collection Process. http://www. meps.ahrq.gov/survey_comp/hc_data_collection.jsp Accessed on December 5, 2006
   Google Scholar
• United States Health Care Financing Administration: The international classification of diseases, 9th rev. Clinical modification: ICD-9-CM, 2nd ed. Washingtion (DC): US Dept. of Health and Human Services, Public Health, US Govt. Printing Office; 1980
   Google Scholar
• Machlin, S, Yu, W, Zodet, M. Computing standard errors for MEPS estimates. Rockville (MD): Agency for Healthcare Research and Quality; January 2005
   Google Scholar
• Mullins CD, Blatt L, Gbarayor CM, et al. Health disparities: a barrier to high-quality care. Am J Health-Syst Pharm 2005;62:1873–82
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005
   Google Scholar
• Nelson KM, Chapko MK, Reiber G, Boyko EJ. The association between health insurance coverage and diabetes care; data from the 2000 Behavioral Risk Factor Surveillance System. Health Serv Res 2005;40:361–72
   PubMed Web of Science ®Google Scholar
• Roe CM, McNamara AM, Motheral BR. Gender- and age-related prescription drug use patterns. Ann Pharmacother 2002;36:30–9
   Google Scholar
• Farley JF, Cline RR, Gupta K. Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporosis Int 2006;17: 395–404
   Google Scholar
• Devine JW, Farley JF, Hadsall RS. Patterns and predictors of prescription medication use in the management of headache: findings from the 2000 Medical Expenditure Panel Survey. Headache 2005;45: 1171–80
   Google Scholar
• Kirby JB, Taliaferro G, Zuvekas SH. Explaining racial and ethnic disparities in health care. Med Care 2006;44: 164–72
   Google Scholar